Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA.

Janet Vargo, Katie Smith, Caroline Knott, Songbai Wang, Chyang Fang, Sherrol McDonough, Cristina Giachetti, Sally Caglioti, Richard Gammon, Denise Gilbert, J. Brooks Jackson, William Richards, Susan Stramer, Larry Mimms

Research output: Contribution to journalArticle

Abstract

BACKGROUND: An HIV-1 and HCV NAT blood screening assay (Procleix HIV-1/HCV, Gen-Probe, Inc.) simultaneously detecting HIV-1 and HCV RNA) has been implemented. Donor plasma samples reactive in the Procleix HIV-1/HCV assay are tested with the HIV-1 and HCV discriminatory assays to resolve whether HIV-1 RNA, HCV RNA, or both are present. STUDY DESIGN AND METHODS: To determine the specificity of the Procleix HIV-1/HCV assay, data were analyzed for samples from 192,288 donations, tested in 16-member pools. To determine sensitivity, data were analyzed for 2014 commercial samples known to contain HIV-1, HCV, or both, as well as 10 HIV-1 and 10 HCV commercial seroconversion panels. RESULTS: The specificity of the Procleix HIV-1/HCV assay was 99.7 percent. The HIV-1 and HCV discriminatory assays showed similar specificity. The sensitivity of the Procleix HIV-1/HCV assay was 99.9, 99.6, and 100 percent, respectively, for samples containing HIV-1, HCV, or both. The Procleix discriminatory assays were comparably sensitive. The Procleix discriminatory assays detected all tested samples of known HIV-1 subtype or HCV genotype. Procleix HIV-1/HCV testing of seroconversion panels showed that the median times to a positive reaction for HIV-1 and HCV were reduced by 3 and 25 days, respectively, compared to serologic tests. CONCLUSION: These studies support the use of the Procleix HIV-1/HCV assay for routine blood donor screening.

Original languageEnglish (US)
Pages (from-to)876-885
Number of pages10
JournalTransfusion
Volume42
Issue number7
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

HIV-1
RNA
Sensitivity and Specificity
Donor Selection
Serologic Tests
Blood Donors
Genotype

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Vargo, J., Smith, K., Knott, C., Wang, S., Fang, C., McDonough, S., ... Mimms, L. (2002). Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion, 42(7), 876-885.

Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. / Vargo, Janet; Smith, Katie; Knott, Caroline; Wang, Songbai; Fang, Chyang; McDonough, Sherrol; Giachetti, Cristina; Caglioti, Sally; Gammon, Richard; Gilbert, Denise; Jackson, J. Brooks; Richards, William; Stramer, Susan; Mimms, Larry.

In: Transfusion, Vol. 42, No. 7, 07.2002, p. 876-885.

Research output: Contribution to journalArticle

Vargo, J, Smith, K, Knott, C, Wang, S, Fang, C, McDonough, S, Giachetti, C, Caglioti, S, Gammon, R, Gilbert, D, Jackson, JB, Richards, W, Stramer, S & Mimms, L 2002, 'Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA.', Transfusion, vol. 42, no. 7, pp. 876-885.
Vargo J, Smith K, Knott C, Wang S, Fang C, McDonough S et al. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion. 2002 Jul;42(7):876-885.
Vargo, Janet ; Smith, Katie ; Knott, Caroline ; Wang, Songbai ; Fang, Chyang ; McDonough, Sherrol ; Giachetti, Cristina ; Caglioti, Sally ; Gammon, Richard ; Gilbert, Denise ; Jackson, J. Brooks ; Richards, William ; Stramer, Susan ; Mimms, Larry. / Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. In: Transfusion. 2002 ; Vol. 42, No. 7. pp. 876-885.
@article{2faadb8f3714453bb5b9826f31c691fe,
title = "Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA.",
abstract = "BACKGROUND: An HIV-1 and HCV NAT blood screening assay (Procleix HIV-1/HCV, Gen-Probe, Inc.) simultaneously detecting HIV-1 and HCV RNA) has been implemented. Donor plasma samples reactive in the Procleix HIV-1/HCV assay are tested with the HIV-1 and HCV discriminatory assays to resolve whether HIV-1 RNA, HCV RNA, or both are present. STUDY DESIGN AND METHODS: To determine the specificity of the Procleix HIV-1/HCV assay, data were analyzed for samples from 192,288 donations, tested in 16-member pools. To determine sensitivity, data were analyzed for 2014 commercial samples known to contain HIV-1, HCV, or both, as well as 10 HIV-1 and 10 HCV commercial seroconversion panels. RESULTS: The specificity of the Procleix HIV-1/HCV assay was 99.7 percent. The HIV-1 and HCV discriminatory assays showed similar specificity. The sensitivity of the Procleix HIV-1/HCV assay was 99.9, 99.6, and 100 percent, respectively, for samples containing HIV-1, HCV, or both. The Procleix discriminatory assays were comparably sensitive. The Procleix discriminatory assays detected all tested samples of known HIV-1 subtype or HCV genotype. Procleix HIV-1/HCV testing of seroconversion panels showed that the median times to a positive reaction for HIV-1 and HCV were reduced by 3 and 25 days, respectively, compared to serologic tests. CONCLUSION: These studies support the use of the Procleix HIV-1/HCV assay for routine blood donor screening.",
author = "Janet Vargo and Katie Smith and Caroline Knott and Songbai Wang and Chyang Fang and Sherrol McDonough and Cristina Giachetti and Sally Caglioti and Richard Gammon and Denise Gilbert and Jackson, {J. Brooks} and William Richards and Susan Stramer and Larry Mimms",
year = "2002",
month = "7",
language = "English (US)",
volume = "42",
pages = "876--885",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA.

AU - Vargo, Janet

AU - Smith, Katie

AU - Knott, Caroline

AU - Wang, Songbai

AU - Fang, Chyang

AU - McDonough, Sherrol

AU - Giachetti, Cristina

AU - Caglioti, Sally

AU - Gammon, Richard

AU - Gilbert, Denise

AU - Jackson, J. Brooks

AU - Richards, William

AU - Stramer, Susan

AU - Mimms, Larry

PY - 2002/7

Y1 - 2002/7

N2 - BACKGROUND: An HIV-1 and HCV NAT blood screening assay (Procleix HIV-1/HCV, Gen-Probe, Inc.) simultaneously detecting HIV-1 and HCV RNA) has been implemented. Donor plasma samples reactive in the Procleix HIV-1/HCV assay are tested with the HIV-1 and HCV discriminatory assays to resolve whether HIV-1 RNA, HCV RNA, or both are present. STUDY DESIGN AND METHODS: To determine the specificity of the Procleix HIV-1/HCV assay, data were analyzed for samples from 192,288 donations, tested in 16-member pools. To determine sensitivity, data were analyzed for 2014 commercial samples known to contain HIV-1, HCV, or both, as well as 10 HIV-1 and 10 HCV commercial seroconversion panels. RESULTS: The specificity of the Procleix HIV-1/HCV assay was 99.7 percent. The HIV-1 and HCV discriminatory assays showed similar specificity. The sensitivity of the Procleix HIV-1/HCV assay was 99.9, 99.6, and 100 percent, respectively, for samples containing HIV-1, HCV, or both. The Procleix discriminatory assays were comparably sensitive. The Procleix discriminatory assays detected all tested samples of known HIV-1 subtype or HCV genotype. Procleix HIV-1/HCV testing of seroconversion panels showed that the median times to a positive reaction for HIV-1 and HCV were reduced by 3 and 25 days, respectively, compared to serologic tests. CONCLUSION: These studies support the use of the Procleix HIV-1/HCV assay for routine blood donor screening.

AB - BACKGROUND: An HIV-1 and HCV NAT blood screening assay (Procleix HIV-1/HCV, Gen-Probe, Inc.) simultaneously detecting HIV-1 and HCV RNA) has been implemented. Donor plasma samples reactive in the Procleix HIV-1/HCV assay are tested with the HIV-1 and HCV discriminatory assays to resolve whether HIV-1 RNA, HCV RNA, or both are present. STUDY DESIGN AND METHODS: To determine the specificity of the Procleix HIV-1/HCV assay, data were analyzed for samples from 192,288 donations, tested in 16-member pools. To determine sensitivity, data were analyzed for 2014 commercial samples known to contain HIV-1, HCV, or both, as well as 10 HIV-1 and 10 HCV commercial seroconversion panels. RESULTS: The specificity of the Procleix HIV-1/HCV assay was 99.7 percent. The HIV-1 and HCV discriminatory assays showed similar specificity. The sensitivity of the Procleix HIV-1/HCV assay was 99.9, 99.6, and 100 percent, respectively, for samples containing HIV-1, HCV, or both. The Procleix discriminatory assays were comparably sensitive. The Procleix discriminatory assays detected all tested samples of known HIV-1 subtype or HCV genotype. Procleix HIV-1/HCV testing of seroconversion panels showed that the median times to a positive reaction for HIV-1 and HCV were reduced by 3 and 25 days, respectively, compared to serologic tests. CONCLUSION: These studies support the use of the Procleix HIV-1/HCV assay for routine blood donor screening.

UR - http://www.scopus.com/inward/record.url?scp=18744395821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744395821&partnerID=8YFLogxK

M3 - Article

C2 - 12375660

AN - SCOPUS:18744395821

VL - 42

SP - 876

EP - 885

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 7

ER -